In reply [10]

Journal of Clinical Oncology

Volumn 25, Issue 5, 2007, Pages

  Duda, Dan G ^a   Cohen, Kenneth S ^a   Au, Patrick ^a   Scadden, David T ^a   Willett, Christopher G ^a   Jain, Rakesh K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CELL SURFACE MARKER; LECTIN;

ANTIANGIOGENIC GENE THERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CELL POPULATION; CELL SIZE; CELL SURFACE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOMAGNETIC SEPARATION; LETTER; PRIORITY JOURNAL; RECTUM CANCER; STEM CELL MOBILIZATION;

EID: 35548979083     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.5100     Document Type: Letter

References (12)

1. Duda DG, Cohen KS, di Tomaso E, et al: Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: Implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449-1453, 2006
2. Ingram DA, Mead LE, Tanaka H, et al: Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104:2752-2760, 2004
3. Goon PK, Boos CJ, Stonelake PS, et al: Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb Haemost 96:45-52, 2006
4. Khan SS, Solomon MA, McCoy JP Jr: Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64:1-8, 2005
5. Elshal MF, Khan SS, Takahashi Y, et al: CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 106:2923-2924, 2005
6. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661, 2001
7. Duda DG, Cohen KS, di Tomaso E, et al: Diferential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers (ASCO 42). J Clin Oncol 24:130s, 2006 (abstr 3038)
8. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
9. Rugo HS, Dickler MN, Traina TA, et al: Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole and bevacizumab (ASCO 42). J Clin Oncol 24:130s, 2006 (abstr 3039)
10. Hagendoorn J, Padera TP, Yock TI, et al: Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol 3:639-697, 2006
11. Willett CG, Boucher Y, Duda DG, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139, 2005
12. Goon PK, Lip GY, Boos CJ, et al: Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8:79-88, 2006